Logo image of LIXT

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) Stock Price, Quote, News and Overview

NASDAQ:LIXT - Nasdaq - US5393193017 - Common Stock - Currency: USD

1.25  -0.09 (-6.72%)

LIXT Quote, Performance and Key Statistics

LIXTE BIOTECHNOLOGY HOLDINGS

NASDAQ:LIXT (5/29/2025, 4:30:02 PM)

1.25

-0.09 (-6.72%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.5
52 Week Low1.02
Market Cap3.35M
Shares2.68M
Float2.19M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06
IPO09-21 2007-09-21


LIXT short term performance overview.The bars show the price performance of LIXT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

LIXT long term performance overview.The bars show the price performance of LIXT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of LIXT is 1.25 USD. In the past month the price decreased by -0.79%. In the past year, price decreased by -46.54%.

LIXTE BIOTECHNOLOGY HOLDINGS / LIXT Daily stock chart

LIXT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.07 327.88B
AMGN AMGEN INC 13.66 152.46B
GILD GILEAD SCIENCES INC 14.36 138.21B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.81B
REGN REGENERON PHARMACEUTICALS 13.66 65.36B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 38.19B
ARGX ARGENX SE - ADR 98.97 35.47B
ONC BEIGENE LTD-ADR 6.32 26.67B
BNTX BIONTECH SE-ADR N/A 24.10B
NTRA NATERA INC N/A 21.58B
SMMT SUMMIT THERAPEUTICS INC N/A 19.47B
BIIB BIOGEN INC 8.39 19.45B

About LIXT

Company Profile

LIXT logo image Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The company is headquartered in East Setauket, New York and currently employs 2 full-time employees. The company went IPO on 2007-09-21. The firm is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. The company is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. The LB-100 series has activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.

Company Info

LIXTE BIOTECHNOLOGY HOLDINGS

No. 2, 248 Route 25A

East Setauket NEW YORK 11733 US

CEO: John S. Kovach

Employees: 4

LIXT Company Website

LIXT Investor Relations

Phone: 13102032902

LIXTE BIOTECHNOLOGY HOLDINGS / LIXT FAQ

What is the stock price of LIXTE BIOTECHNOLOGY HOLDINGS today?

The current stock price of LIXT is 1.25 USD. The price decreased by -6.72% in the last trading session.


What is the ticker symbol for LIXTE BIOTECHNOLOGY HOLDINGS stock?

The exchange symbol of LIXTE BIOTECHNOLOGY HOLDINGS is LIXT and it is listed on the Nasdaq exchange.


On which exchange is LIXT stock listed?

LIXT stock is listed on the Nasdaq exchange.


What is LIXTE BIOTECHNOLOGY HOLDINGS worth?

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) has a market capitalization of 3.35M USD. This makes LIXT a Nano Cap stock.


How many employees does LIXTE BIOTECHNOLOGY HOLDINGS have?

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) currently has 4 employees.


What are the support and resistance levels for LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) stock?

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) has a support level at 1.22 and a resistance level at 1.33. Check the full technical report for a detailed analysis of LIXT support and resistance levels.


Should I buy LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) stock pay dividends?

LIXT does not pay a dividend.


When does LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) report earnings?

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) will report earnings on 2025-08-06.


What is the Price/Earnings (PE) ratio of LIXTE BIOTECHNOLOGY HOLDINGS (LIXT)?

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.45).


What is the Short Interest ratio of LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) stock?

The outstanding short interest for LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) is 0.9% of its float. Check the ownership tab for more information on the LIXT short interest.


LIXT Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to LIXT. When comparing the yearly performance of all stocks, LIXT is a bad performer in the overall market: 85.72% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

LIXT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to LIXT. LIXT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LIXT Financial Highlights

Over the last trailing twelve months LIXT reported a non-GAAP Earnings per Share(EPS) of -1.45. The EPS increased by 39.12% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -219.54%
ROE -286.79%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%33.51%
Sales Q2Q%N/A
EPS 1Y (TTM)39.12%
Revenue 1Y (TTM)N/A

LIXT Ownership and Analysts


Ownership
Inst Owners11.28%
Ins Owners8.1%
Short Float %0.9%
Short Ratio1.1
Analysts
Analysts0
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A